TY - JOUR
T1 - 5α-Reductases in human breast carcinoma
T2 - Possible modulator of in situ androgenic actions
AU - Suzuki, Takashi
AU - Darnel, Andrew D.
AU - Akahira, Jun Ichi
AU - Ariga, Naohiro
AU - Ogawa, Sayaka
AU - Kaneko, Chika
AU - Takeyama, Junji
AU - Moriya, Takuya
AU - Sasano, Hironobu
PY - 2001
Y1 - 2001
N2 - The expression of 5α-reductase types 1 and 2 was examined in human breast carcinoma using immunohistochemistry and RT-PCR. Immunoreactivity for 5α-reductase isozymes was also correlated with various clinicopathological parameters to examine possible local regulatory mechanisms of sex steroids, including progesterone and androgens, in human breast carcinoma tissues. Immunoreactivity for 5α-reductase type 1 was detected in the cytoplasm and possibly in the nuclear membrane of tumor cells in 35 of 60 invasive ductal carcinomas (58%), and type 2 signal was detected in 9 of these 60 cases (15%). The results from RT-PCR (n = 8) were consistent with those from immunohistochemistry. A significant positive correlation was detected between 5α-reductase type 1 immunoreactivity and androgen and progesterone receptor A or B labeling indexes, and immunoreactivities of 5α-reductase type 2, 17β-hydroxysteroid dehydrogenase type 5, or 3β-hydroxysteroid dehydrogenase, which recognizes both types I and II. An inverse correlation was detected between 5α-reductase type 1 immunoreactivity and tumor size, histological grade, or Ki-67 labeling index. 5α-Reductase type 2 immunoreactivity was significantly correlated with 17β-hydroxysteroid dehydrogenase type 5 immunoreactivity, but not with other parameters. This study suggests that 5α-reductase type 1 is mainly expressed in human breast carcinoma, which may play an important role in the in situ production and actions of the potent androgen, 5α-dihydrotestosterone, including inhibition of cancer cell proliferation, in hormone-dependent human breast carcinoma.
AB - The expression of 5α-reductase types 1 and 2 was examined in human breast carcinoma using immunohistochemistry and RT-PCR. Immunoreactivity for 5α-reductase isozymes was also correlated with various clinicopathological parameters to examine possible local regulatory mechanisms of sex steroids, including progesterone and androgens, in human breast carcinoma tissues. Immunoreactivity for 5α-reductase type 1 was detected in the cytoplasm and possibly in the nuclear membrane of tumor cells in 35 of 60 invasive ductal carcinomas (58%), and type 2 signal was detected in 9 of these 60 cases (15%). The results from RT-PCR (n = 8) were consistent with those from immunohistochemistry. A significant positive correlation was detected between 5α-reductase type 1 immunoreactivity and androgen and progesterone receptor A or B labeling indexes, and immunoreactivities of 5α-reductase type 2, 17β-hydroxysteroid dehydrogenase type 5, or 3β-hydroxysteroid dehydrogenase, which recognizes both types I and II. An inverse correlation was detected between 5α-reductase type 1 immunoreactivity and tumor size, histological grade, or Ki-67 labeling index. 5α-Reductase type 2 immunoreactivity was significantly correlated with 17β-hydroxysteroid dehydrogenase type 5 immunoreactivity, but not with other parameters. This study suggests that 5α-reductase type 1 is mainly expressed in human breast carcinoma, which may play an important role in the in situ production and actions of the potent androgen, 5α-dihydrotestosterone, including inhibition of cancer cell proliferation, in hormone-dependent human breast carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0034744032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034744032&partnerID=8YFLogxK
U2 - 10.1210/jc.86.5.2250
DO - 10.1210/jc.86.5.2250
M3 - Article
C2 - 11344235
AN - SCOPUS:0034744032
VL - 86
SP - 2250
EP - 2257
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 5
ER -